newsfilter
← Earnings
Earnings Releases·

Bluejay Diagnostics — Third Quarter 2026 Earnings Summary

Bluejay Diagnostics completed enrollment in its SYMON-II clinical validation study with 777 evaluable patients, exceeding the original target of 750. The company established an alternative manufacturing facility ahead of a contractual deadline and advanced U.S. commercial infrastructure through new distribution agreements. As of September 30, 2026, the company held $7.38 million in cash and projects these resources will sustain operations through the second quarter of 2027. Bluejay aims to submit an FDA 510(k) application for its Symphony IL-6 test during the first half of 2027.

Company
BLUEJAY DIAGNOSTICS INC
Sector
Healthcare
Industry
Medical Devices